NRx: ZYESAMI® (aviptadil) US Expanded Access and Right to Try Programs for Patients with COVID

 

• ZYESAMI® (aviptadil) is currently in a Phase 3 clinical trial being conducted by the National Institutes of Health (NIH)

• NRx will continue to provide ZYESAMI to hospitals enrolled in NRx’s Expanded Access Protocol under US Food and Drug Administration guidelines

• NRx is also making ZYESAMI available as an investigational medicine under the Federal Right to Try Act1

• ZYESAMI is available to patients who have progressed despite treatment with remdesivir and other approved medicines and who are not able to participate in the NIH trial

• NRx manufacturing program now supports increases in demand under Expanded Access and Federal Right to Try programs

https://finance.yahoo.com/news/nrx-pharmaceuticals-announces-expansion-zyesami-114800247.html